⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
9361 persons with systolic BP ≥130 mmHg and high CV risk, without diabetes, were randomized to systolic target <120 mmHg (intensive) vs <140 mmHg (standard). Trial stopped early after 3.26 years: primary composite outcome (MI, ACS, stroke, HF, CV death) 1.65%/yr vs 2.19%/yr (HR 0.75, 95% CI 0.64–0.89, p<0.001). All-cause mortality also lower (HR 0.73, p=0.003). Higher rates of hypotension, syncope, electrolyte abnormalities, and AKI in intensive group. Funded by NIH.
Coeff. authors = avg(0.65, 1.00) = 0.83
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.83, 0.95) = 0.83← lowest dominates
Final coefficient : 0.83
Final score = 48.5/52.8 × 0.83 × 100 = 76/100
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B — 2015 · New England Journal of Medicine
Contrasted resultsCardiovascular Disease, Drug Therapy, and Mortality in Covid-19.
Mehra MR — 2020 · The New England Journal of Medicine
Contrasted resultsDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV — 2019 · The New England journal of medicine
Contrasted resultsCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL — 2018 · The New England journal of medicine
Contrasted resultsEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS — 2017 · The New England journal of medicine